Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Anti-idiotypic
Reexamination Certificate
2006-07-18
2011-12-06
Bristol, Lynn (Department: 1643)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Anti-idiotypic
C530S387200, C536S023530
Reexamination Certificate
active
08071094
ABSTRACT:
The present invention is related to a monoclonal anti-idiotypic antibody directed against a Factor VIII inhibitor antibody binding to the domain A2 of Factor VIII, and to a cell line producing this monoclonal anti-idiotypic antibody, to the use of this monoclonal anti-idiotypic antibody as drug, and more particularly, to its use for the manufacturing of a drug to be used for the treatment of haemophilia A.
REFERENCES:
patent: 5530101 (1996-06-01), Queen et al.
patent: 7364735 (2008-04-01), Voorberg et al.
patent: 2006/0239998 (2006-10-01), Gilles et al.
patent: 2008/0160015 (2008-07-01), Gilles et al.
patent: WO 2004/014955 (2004-02-01), None
Jang et al. (Molec. Immunol. 35:1207-1217 (1998)).
Brorson et al. (J. Immunol. 163:6694-6701 (1999)).
Coleman (Research in Immunol. 145:33-36 (1994)).
Casset et al. ((2003) BBRC 307, 198-205).
Holm et al (Molec. Immunol. (2007) 44, 1075-1084).
MacCallum et al. (J. Mol. Biol. (1996) 262, 732-745).
Ananyeva et al. (Blood Coagul. Fibrinolysis 15(2):109-124 (Mar. 2004)).
Scandella et al. (Blood 82:1767 (1993)).
Fundamental Immunology 242 (William E. Paul, M.D. ed., 3d ed. 1993).
ATCC search output for: IR983F, PERC6, CHO-Lec10, CHO-Lec1, CHO-Lec13 and Sp2/0-Ag 14, (Nov. 30, 2007).
Janeway et al. (Immunobiology, third edition, Garland Press, 1997, pp. 3:7-11).
Rudikoff et al (Proc Natl Acad Sci USA 79 p. 1979 (1982)).
Jones, Peter T. et al., “Replacing the complementanty-deterimining regions in a human antibody with those from a mouse”, Nature vol. 321, 1986, pp. 522-525.
Riechmann, Lutz et al., “Reshaping human antibodies for therapy”, Nature vol. 332, 1988, 323-327.
Madec, Anne-Marie et al., “Four IgG anti-islet human monoclonal antihodies isolated from a type 1 diabetes patient recognize distinct epitopes of glutamic acid decarboxylase 65 and are somatically mutated”, The Journal of Immunology, vol. 156, 1996, 3541-3649.
Sato, Koh et al., “Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth”, Cancer Research, vol. 53, 1993, 651-868.
Giles, Jean Guy et al., “In vivo neutralization of a C2 domain-specific human anti-factor VIII inhibitor by an anti-adiotypic antibody”, Blood, vol. 103, 2004 2617-2823.
Lubahn, Beth C. et al., “Characterization of a monoclonal anti-idiotype antibody to human anti-factor VIII antibodies”, Proc. Natl. Academy of Science, vol. 87, 1990, 8232-8236.
Healy, John F. et al., “Residues 484-508 contain a major determinant of the inhibitory epitope in the A2 domain of human factor VIII”, The Journal of Biological Chemistry, vol. 270, 1995, 14505-14509.
Dietrich, Gilles et el., “A monoclonal anti-idiotypic antibody against the antigen-combining site of anti-factor VIII autoantibodies defines an idiotope that is recognized by normal human polyspecific immunoglobulins for therapeutic use (IVIg)”, Journal of Autoimmunity, vol. 3, 1990, 647-557.
Gilles, Jean Guy G. et al., “Antibodies to idiotypes of human monoclonal anti-factor VIII (FVIII) antibodies neutralise their inhibitory activity”, Transfusion iVtedicine II, Abstract No. 2048, p. 460a, XP001109476, Dec. 1999.
Saint-Remy, Jean Marie et al., “Anti-Idiotybio Antibodies: From Regulation to Therapy of Factor VIII Innibitors” Vox Sang 1999;77(suppl 1):21-24.
Lollar, Pete et al., “Inhibition of Human Factor Villa by Anti-A2 Subunit Antibodies” J. Clin. Invest vol. 93, Jun. 1994, pp. 2497-2504.
Fay, Philip et al., “Model for the Factor Villa-dependent Decay of the Intrinsic Factor Xase” J. Biol. Chem. vol. 271, No. 11, 1996, pp. 6027-5032.
Morrison, Sherie el al., “Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region domains” Proc. Nat. Acad. Sci. USA vol. 81, pp, 6851-6856, Nov. 1984.
Wood et al.,“Expression of active human factor VIII from reciombinant DNA clones,” Nature (1984) 312:330-337.
Gilles J.G. et al., “Anti-Factor VIII Antibodies of Hemophiliac Patients Are Frequently Directed Towards Nonfunctional Determinants and Do Not Exhibit Isotypic Restriction,” (1993) Blood; vol. 82, No. 8, pp. 2452-2461.
Jarvis et al., “Induction of Human Factor VIII Inhibitors in Rats by Immunization with Human Recombinant Factor VIII: a Small Animal Model for Humans with Higher Responder Inhibitor Phenotype” Thrombosis and Haemostasis Feb. 1996; 75(2)318-25.
Jacquemin, Marc et al., “A human antibody directed to the factor VIII C1 domain inhibits factor VIII cofactor activity and binding to von Willebrand factor” (2000) Blood 95:155-163.
Jaquemin, Marc et al., “Mechanism and Kinetics of Factor VIII Inactivation: Study With an IgG4 Monoclonal Antibody Derived From a Hemophilia A Patient With Inhibitor,” Blood 1995 Jul. 15: 92(496-506).
Ananyeva, Natalya et al., “inhibitors in homoohilla A: mechanisms of inhibition, management and perspectives,” (2004) Blood Coagulation and Fibrinolysis. Mar: 15(2)109-124.
Behrens Christian
Gilles Jean Guy
Jacquemin Marc
Saint-Remy Jean-Marie
Birch & Stewart Kolasch & Birch, LLP
Bristol Lynn
Laboratoire Francais du Fractionement Et des Biotechnologies
LandOfFree
Anti-idiotypic antibody neutralizing the inhibitor activity... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-idiotypic antibody neutralizing the inhibitor activity..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-idiotypic antibody neutralizing the inhibitor activity... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4263833